Noxopharm surges 13% as anti-inflammatory drug effective in COVID-19 patients

Noxopharm

23/08/2021 07:09

** Shares of Australia's Noxopharm Ltd  NOX.AX  jump as much
as 13.5% to A$0.63, their biggest intraday pct gain since May 31
    ** The drug developer says its anti-inflammatory drug,
Veyonda, does not compromise the ability of the body to fight
coronavirus infection  urn:newsml:reuters.com:*:nFWN2PS0KB
    ** Stock hits highest since July 27 before paring gains to
trade at A$0.58
    ** NOX had been on trading halt since Aug 19
    ** Stock up 13.3% so far this year, as of close on Aug 18

 (Reporting by Dhriti Garg in Bengaluru)
 ((Dhriti.Garg@thomsonreuters.com))